Biocomposites Expands Product Portfolio | Launches SYNICEM Spacers in the UK

Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce the launch of SYNICEMTM hip, knee and shoulder preformed spacers in the United Kingdom, and their successful use in patients undergoing joint surgery.

SYNICEM spacers are antibiotic-loaded, preformed spacers which overcome the challenges of traditional intra-operative moulded and handmade spacers. They help support surgeons’ revisions of the hip, knee and shoulder by preserving articular space and aiding the treatment of infection. Precision-engineered for consistency and structural uniformity, SYNICEMTM spacers provide a high local concentration of gentamicin and provide case-by-case flexibility to save surgeons’ time during their procedures.

The launch of SYNICEMTM spacers in the UK follows Biocomposites’ acquisition of French-based medical device manufacturer, Synimed, in 2022.  Synimed specialises in bone cement and polymer-related products using in-house proprietary core polymer production and formulation.

Rohit Dhawan, Consultant Orthopaedic Surgeon, Royal United Hospitals Bath NHS Foundation Trust, commented: “Biocomposites’ SYNICEM spacers are really useful for orthopaedic surgeons who deal with infections.  Ready to use and available in a variety of sizes to fit different patient anatomies, they provide the flexibility to enable a swift procedure, leaving patients infection-free and able to resume their day-to-day activities. I am delighted that they will now be readily available in the UK.”

Michael Harris, Chief Executive Officer of Biocomposites, said: “I’m delighted that our acquisition of Synimed has enriched our portfolio of products that support surgeon’s managing and treating infection. SYNICEM spacers already help many patients throughout the world and bringing them into the UK and wider Biocomposites network will ensure that more patients benefit.”

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism. I sincerely thank all the investigators for their commitment and dedication,” said William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™.
The combined expertise of Cordance Medical and the Airan and Williams Labs will see NeuroAccess utilized to deliver a novel application of drug-loaded nanoparticles, providing targeted drug delivery to the brain.
Medixine prepares for 2024 with two key senior hires, VP of Operations in the U.S. and VP of Engineering in Finland. The appointments will enhance support and service to the company’s U.S.-based partners, including leading respiratory homecare provider Lincare and a major medical device manufacturer. In addition, the new hires will enable streamlined design, testing, and deployment of new product features for more patient-centric, cost and time-effective treatment of chronic conditions.
Innovent Biologics and Synaffix: Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to receive an upfront payment plus potentialmilestone payments and royalties on commercial sales for each licensed target.
Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.

By using this website you agree to accept Medical Device News Magazine Privacy Policy